S1054 Barriers to Inflammatory Bowel Disease (IBD) Care in a Racially and Ethnically Diverse Population: Patient Survey and Chart Review Study

2022. We investigated the prevalence of myocarditis in CD compared to patients with no IBD. Also, we compared the prevalence between CD patients with and without immune-modifying agents. Results: Of the 70, 301,380 individuals in the database from 1999 to present, we identi fi ed 249,300 (0.3%) patients with CD, of whom 40,840 (16.4%) patients received anti-TNFs. CD patients were 59.4% females, 76% Caucasian , and 70% in 18-65 years age group. The prevalence of myocarditis was 0.12% for CD compared to 0.04% in individuals without IBD, p , 0.001. Compared to the patients withCDhad , 0.0001].AmongCD, havingmyocarditisincludedbeing elderly( 65y/o), history of type diabetes (P , 0.0001). prevalence of myocarditis was signi cantly lower CD patients on anti-TNF , and thiopurines p , whereas methotrexate and 5-aminosalicylates (5-ASA) had higher rates , 5 0.0001], respectively. signi association. Our fi ndings may have signi fi cant implications for patients with cardiac risk factors and underlying myocardial